Home LiteratureArticle Details
PMID: 20626868 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia.

Molecular cancer ·Vol. 9 ·2010-07-13 ·Pages 191

Flamant L, Notte A, Ninane N, Raes M, Michiels C

Abstract

Hypoxia is a hallmark of solid tumors and is associated with metastases, therapeutic resistance and poor patient survival. In this study, we showed that hypoxia protected MDA-MB-231 breast cancer cells against paclitaxel- but not epirubicin-induced apoptosis. The possible implication of HIF-1 and AP-1 in the hypoxia-induced anti-apoptotic pathway was investigated by the use of specific siRNA. Specific inhibition of the expression of these two transcription factors was shown to increase apoptosis induced by chemotherapeutic agents under hypoxia indicating an involvement of HIF-1 and AP-1 in the anti-apoptotic effect of hypoxia. After HIF-1 specific inhibition and using TaqMan Human Apoptosis Array, 8 potential HIF-1 target genes were identified which could take part in this protection. Furthermore, Mcl-1 was shown to be a potential AP-1 target gene which could also participate to the hypoxia-induced chemoresistance. Altogether, these data highlight two mechanisms by which hypoxia could mediate its protective role via the activation of two transcription factors and, consecutively, changes in gene expression encoding different anti- and pro-apoptotic proteins.

MeSH Terms
Antineoplastic Agents, Phytogenic/pharmacology Apoptosis/drug effects,physiology Cell Hypoxia Cell Line, Tumor Female Humans Hypoxia-Inducible Factor 1, alpha Subunit/physiology Paclitaxel/pharmacology RNA, Small Interfering Transcription Factor AP-1/physiology
Chemicals
Antineoplastic Agents, Phytogenic HIF1A protein, human Hypoxia-Inducible Factor 1, alpha Subunit RNA, Small Interfering Transcription Factor AP-1 Paclitaxel
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Flamant Lionel
Laboratory of Biochemistry and cellular Biology (URBC), NARILIS - NAmur Research Institute for LIfe Sciences - FUNDP-University of Namur, 5000 Namur, Belgium.
Notte Annick
Ninane Noelle
Raes Martine
Michiels Carine
References (64)
64 references, click to expand
  1. Mcl-1 is a potential therapeutic target in multiple types of cancer.
    Cell Mol Life Sci. 2009 Apr;66(8):1326-36 PMID: 19099185
  2. Antiapoptotic action of hypoxia-inducible factor-1 alpha in human endothelial cells.
    Lab Invest. 2004 May;84(5):553-61 PMID: 15064771
  3. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements.
    Cancer Res. 1991 Jun 15;51(12):3316-22 PMID: 2040005
  4. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Cancer Chemother Pharmacol. 2006 Dec;58(6):776-84 PMID: 16532342
  5. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.
    Cancer Treat Rev. 2003 Aug;29(4):297-307 PMID: 12927570
  6. Mitochondrial autophagy: life and breath of the cell.
    Autophagy. 2008 May;4(4):534-6 PMID: 18376135
  7. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
    Cancer Res. 1999 Dec 1;59(23):5863-70 PMID: 10606224
  8. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis.
    J Biol Chem. 2005 Mar 11;280(10):9336-44 PMID: 15611089
  9. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Clin Cancer Res. 2004 Apr 1;10(7):2299-306 PMID: 15073105
  10. Hypoxia-responsive transcription factors.
    Pflugers Arch. 2005 Sep;450(6):363-71 PMID: 16007431
  11. Tumor hypoxia, drug resistance, and metastases.
    J Natl Cancer Inst. 1990 Mar 7;82(5):338-9 PMID: 2406450
  12. Cell autonomous apoptosis defects in acid sphingomyelinase knockout fibroblasts.
    J Biol Chem. 2001 Jan 5;276(1):442-8 PMID: 11031259
  13. Role of Jun and Jun kinase in resistance of cancer cells to therapy.
    Drug Resist Updat. 2003 Jun;6(3):147-56 PMID: 12860462
  14. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors.
    Cancer Res. 2001 Sep 15;61(18):6669-73 PMID: 11559532
  15. Can gene therapy overcome the problem of hypoxia in radiotherapy?
    J Radiat Res. 2000 Sep;41(3):201-12 PMID: 11210824
  16. Mcl-1.
    Int J Biochem Cell Biol. 2005 Feb;37(2):267-71 PMID: 15474972
  17. Current options in treatment of anthracycline-resistant breast cancer.
    Cancer Treat Rev. 1999 Oct;25(5):279-91 PMID: 10544072
  18. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells.
    Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2353-8 PMID: 19168635
  19. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
    Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 PMID: 7539918
  20. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression.
    Anticancer Agents Med Chem. 2008 Oct;8(7):790-7 PMID: 18855580
  21. Hypoxia and cancer.
    J Mol Med (Berl). 2007 Dec;85(12):1301-7 PMID: 18026916
  22. Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element.
    Clin Chim Acta. 2008 Sep;395(1-2):6-13 PMID: 18505681
  23. Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells.
    Cancer Chemother Pharmacol. 2006 Oct;58(4):540-6 PMID: 16520989
  24. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia.
    J Biol Chem. 2008 Apr 18;283(16):10892-903 PMID: 18281291
  25. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Cancer Gene Ther. 2004 Oct;11(10):691-8 PMID: 15354201
  26. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway.
    Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92 PMID: 9653127
  27. Apo2L/TRAIL and its death and decoy receptors.
    Cell Death Differ. 2003 Jan;10(1):66-75 PMID: 12655296
  28. Transcriptional regulation by transforming growth factor beta of the expression of retinoic acid and retinoid X receptor genes in osteoblastic cells is mediated through AP-1.
    J Biol Chem. 1996 Dec 6;271(49):31602-6 PMID: 8940178
  29. Effect of hypoxia-inducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide.
    Neurochem Res. 2009 May;34(5):984-90 PMID: 18937067
  30. Hypoxia--a key regulatory factor in tumour growth.
    Nat Rev Cancer. 2002 Jan;2(1):38-47 PMID: 11902584
  31. Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines.
    Mol Cancer. 2007 Sep 26;6:61 PMID: 17894897
  32. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.
    Cancer Res. 2002 Jun 15;62(12):3387-94 PMID: 12067980
  33. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis.
    J Biol Chem. 2001 Jun 22;276(25):22368-74 PMID: 11294857
  34. Modulation of death receptors by cancer therapeutic agents.
    Cancer Biol Ther. 2008 Feb;7(2):163-73 PMID: 18059181
  35. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer.
    Cancer Sci. 2008 Jan;99(1):121-8 PMID: 17953712
  36. Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest.
    Biochem Pharmacol. 2007 Feb 15;73(4):481-90 PMID: 17126817
  37. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells.
    Mol Cancer Ther. 2006 Sep;5(9):2241-50 PMID: 16985058
  38. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha.
    J Biol Chem. 1999 Jan 22;274(4):2060-71 PMID: 9890965
  39. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate.
    Biochem Biophys Res Commun. 2006 Apr 21;342(4):1341-51 PMID: 16516853
  40. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro.
    Br J Cancer. 2003 Dec 1;89(11):2133-9 PMID: 14647149
  41. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
    Science. 2001 Apr 20;292(5516):464-8 PMID: 11292862
  42. Hypoxia-inducible factors: central regulators of the tumor phenotype.
    Curr Opin Genet Dev. 2007 Feb;17(1):71-7 PMID: 17208433
  43. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.
    Genes Dev. 2002 Jun 15;16(12):1466-71 PMID: 12080085
  44. Hypoxia and drug resistance.
    Cancer Metastasis Rev. 1994 Jun;13(2):139-68 PMID: 7923547
  45. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
    J Clin Oncol. 2000 May;18(10):2116-25 PMID: 10811677
  46. Employing tumor hypoxia for oncolytic therapy in breast cancer.
    J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):311-8 PMID: 16826462
  47. Is HIF-1alpha a pro- or an anti-apoptotic protein?
    Biochem Pharmacol. 2002 Sep;64(5-6):889-92 PMID: 12213583
  48. Drug resistance and the solid tumor microenvironment.
    J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 PMID: 17895480
  49. Role of hypoxia in the hallmarks of human cancer.
    J Cell Biochem. 2009 Aug 15;107(6):1053-62 PMID: 19479945
  50. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells.
    Pol J Pharmacol. 2004 Jul-Aug;56(4):435-44 PMID: 15520498
  51. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment.
    Cancer Metastasis Rev. 2007 Jun;26(2):241-8 PMID: 17440683
  52. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.
    Cancer. 2000 Jun 1;88(11):2619-28 PMID: 10861441
  53. Paclitaxel: epirubicin in metastatic breast cancer--a review.
    Ann Oncol. 2001 May;12(5):593-8 PMID: 11432615
  54. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract.
    J Biol Chem. 1998 Apr 10;273(15):9158-67 PMID: 9535906
  55. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
    Cancer Res. 1998 Apr 1;58(7):1408-16 PMID: 9537241
  56. Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity.
    Mol Cancer. 2008 Mar 26;7:27 PMID: 18366759
  57. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.
    Mol Cell Biol. 2004 Apr;24(7):2875-89 PMID: 15024076
  58. Effects of hypoxia on tumor metabolism.
    Cancer Metastasis Rev. 2007 Jun;26(2):291-8 PMID: 17415528
  59. HIF-1alpha has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression.
    J Cell Biochem. 2006 Mar 1;97(4):755-65 PMID: 16229017
  60. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia.
    Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9082-7 PMID: 10922063
  61. Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway.
    Exp Cell Res. 2006 Sep 10;312(15):2908-20 PMID: 16844113
  62. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Acta Oncol. 2006;45(5):590-6 PMID: 16864174
  63. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    J Invest Dermatol. 2005 Nov;125(5):1010-9 PMID: 16297203
  64. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.
    J Natl Cancer Inst. 2001 Feb 21;93(4):266-76 PMID: 11181773
Article Info
Journal
Molecular cancer
Abbr.
Mol Cancer
ISSN
1476-4598
Published
2010-07-13
Epub
2010-00-13
Pages
191
Language
English
Region
England
NLM ID
101147698
PMCID
PMC3098009
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com